Literature DB >> 13138868

Observations on the combined use of pyrazinamide (Aldinamide) and isoniazid in the treatment of pulmonary tuberculosis; a clinical study.

M CAMPAGNA, A CALIX, G HAUSER.   

Abstract

Entities:  

Keywords:  NICOTINIC ACID ISOMERS/therapeutic use; NICOTINIC ACID/derivatives; TUBERCULOSIS, PULMONARY/therapy

Mesh：

Substances：

Year:  1954        PMID： 13138868     DOI： 10.1164/art.1954.69.3.334

Source DB:  PubMed          Journal:  Am Rev Tuberc        ISSN： 0096-0381


× No keyword cloud information.
  5 in total

1.  Hyperuricaemia due to pyrazinamide.

Authors:  J SCHNEEWEISS; G W POOLE
Journal:  Br Med J       Date:  1960-09-17

2.  Clinical and toxicodynamic evidence that high-dose pyrazinamide is not more hepatotoxic than the low doses currently used.

Authors:  Jotam G Pasipanodya; Tawanda Gumbo
Journal:  Antimicrob Agents Chemother       Date:  2010-05-03       Impact factor: 5.191

Review 3.  Treatment of active pulmonary tuberculosis in adults: current standards and recent advances. Insights from the Society of Infectious Diseases Pharmacists.

Authors:  Ronald G Hall; Richard D Leff; Tawanda Gumbo
Journal:  Pharmacotherapy       Date:  2009-12       Impact factor: 4.705

4.  Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis.

Authors:  Payam Nahid; Susan E Dorman; Narges Alipanah; Pennan M Barry; Jan L Brozek; Adithya Cattamanchi; Lelia H Chaisson; Richard E Chaisson; Charles L Daley; Malgosia Grzemska; Julie M Higashi; Christine S Ho; Philip C Hopewell; Salmaan A Keshavjee; Christian Lienhardt; Richard Menzies; Cynthia Merrifield; Masahiro Narita; Rick O'Brien; Charles A Peloquin; Ann Raftery; Jussi Saukkonen; H Simon Schaaf; Giovanni Sotgiu; Jeffrey R Starke; Giovanni Battista Migliori; Andrew Vernon
Journal:  Clin Infect Dis       Date:  2016-08-10       Impact factor: 9.079

5.  Optimising pyrazinamide for the treatment of tuberculosis.

Authors:  Nan Zhang; Radojka M Savic; Martin J Boeree; Charles A Peloquin; Marc Weiner; Norbert Heinrich; Erin Bliven-Sizemore; Patrick P J Phillips; Michael Hoelscher; William Whitworth; Glenn Morlock; James Posey; Jason E Stout; William Mac Kenzie; Robert Aarnoutse; Kelly E Dooley
Journal:  Eur Respir J       Date:  2021-07-20       Impact factor: 33.795
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.